14 November 2012

Diabetes worldwide at a record high

Diabetes is running at record levels worldwide and half the people estimated to have the disease are, as yet, undiagnosed, according to a report.


Diabetes is running at record levels worldwide and half the people estimated to have the disease are, as yet, undiagnosed, according to a report.

The number of people living with diabetes is now put at 371 million, up from 366 million a year ago, with numbers expected to reach 552 million by 2030, the International Diabetes Federation (IDF) said.

Diabetes is often viewed as a western problem, since the vast majority of people have type 2 diabetes which is linked to obesity and lack of exercise.

But the disease is also spreading rapidly in poorer countries, alongside urbanisation, and four out of five diabetics now live in low and middle-income countries, opening up new opportunities and challenges for the drug industry.

Hidden burden in Africa

China alone has 92.3 million people with diabetes, more than any other nation in the world, and the hidden burden is also enormous in sub-Saharan Africa where limited healthcare means less than a fifth of cases get diagnosed.

The IDF estimates that, globally, 187 million people do not yet know they are suffering from the condition.

Diabetics have inadequate blood sugar control which can lead to serious complications, including nerve and kidney damage and blindness. Worldwide deaths from the disease are running at 4.8 million a year.

The disease is one of a number of chronic conditions - along with cancer, cardiovascular and respiratory diseases - that healthcare campaigners want included in the next set of global development goals, which will replace outgoing Millennium Developments Goals in 2015.

For the international drugmakers, diabetes offers riches, with global sales of diabetes medicines expected to reach $48-$53 billion by 2016, up from $39.2 billion in 2011, according to research firm IMS Health.

More countries trying to meet demands

Tapping into the potential of increased demand in emerging markets, however, requires a twin-track approach from drug companies which have traditionally focused on pricey new therapies for rich-world markets.

These days, there is a lot more focus on high-volume but lower-margin business in developing economies, many of which are predicted to show high double-digit percentage sales growth for diabetes medicines for years to come.

The shift is already yielding results.

China, for example, is now the second-largest market behind the United States for the world's biggest maker of insulin - Danish group Novo Nordisk. It is also a major focus for rivals such as Eli Lilly, Merck & Co, and Sanofi.

Poorer countries are more difficult, especially when it comes to insulin, which must be kept cool if it is not to deteriorate. While most patients start on cheap generic diabetes pills, such as metformin, many need insulin as their disease progresses.

Still, Novo Nordisk thinks it has cracked part of the problem in Kenya, where a project using churches and other local groups has reduced the number of middlemen in the supply chain and cut the cost of a month's supply of insulin to around 500 Kenyan shillings ($6).

So far, the project only covers around 1 000 Kenyans but Jesper Hoiland, Novo's head of international operations, is confident his company's low-price model will become profitable as it increases in scale. "It will take three to five years to get to breakeven," he said in an interview.

In the meantime, similar pilot schemes are being tested in rural India and Nigeria.

Other major drugmakers like Sanofi, which has a significant presence in Africa, are also adopting "tiered" or differential pricing to open up developing world markets. ($1 = 85.3500 Kenyan shillings).

(Reuters, November 2012)

Read more:

Who is at risk of diabetes?


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules